title: Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
abstract: Previous studies have suggested that development of inhibitors in previously treated patients (PTPs) may be attributable to a switch in factor VIII (FVIII) therapeutic product. Consequently, it is widely recognized that inhibitor development must be assessed in PTPs following the introduction of any new FVIII product. Following a national tender process in 2006, all patients with haemophilia A in Ireland changed their FVIII treatment product en masse to a plasma and albumin-free recombinant full-length FVIII product (ADVATE(®)). In this study, we retrospectively reviewed the case records of Irish PTPs to evaluate risk of inhibitor formation following this treatment switch. One hundred and thirteen patients participated in the study. Most patients (89%) had severe haemophilia. Only one of 96 patients with no inhibitor history developed an inhibitor. Prior to the switch in his recombinant FVIII (rFVIII) treatment of choice, this child had only experienced three exposure days (EDs). Consequently, in total he had only received 6 EDs when his inhibitor was first diagnosed. In keeping with this lack of de novo inhibitor development, we observed no evidence of any recurrent inhibitor formation in any of 16 patients with previously documented inhibitors. Similarly, following a previous en masse switch, we have previously reported that changing from a Chinese hamster ovary cell-produced to a baby hamster kidney cell-produced rFVIII was also associated with a low risk of inhibitor formation in PTPs. Our cumulative findings from these two studies clearly emphasizes that the risk of inhibitor development for PTPs following changes in commercial rFVIII product is low, at least in the Irish population.
authors.affiliation: National Centre for Hereditary Coagulation Disorders, St. James's Hospital, Dublin, Ireland.
authors.forename: C L
authors.initials: CL
authors.lastname: Bacon
authors.forename: E
authors.initials: E
authors.lastname: Singleton
authors.forename: B
authors.initials: B
authors.lastname: Brady
authors.forename: B
authors.initials: B
authors.lastname: White
authors.forename: B
authors.initials: B
authors.lastname: Nolan
authors.forename: R M
authors.initials: RM
authors.lastname: Gilmore
authors.forename: C
authors.initials: C
authors.lastname: Ryan
authors.forename: C
authors.initials: C
authors.lastname: Keohane
authors.forename: P Vince
authors.initials: PV
authors.lastname: Jenkins
authors.forename: J S
authors.initials: JS
authors.lastname: O'Donnell
mesh_terms: D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000032:analysis*; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D005169:Factor VIII / Q000276:immunology* / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D011994:Recombinant Proteins / Q000097:blood; D012189:Retrospective Studies; D012709:Serum Albumin; D055815:Young Adult
chemical_list: D001323:Autoantibodies; D019774:Blood Coagulation Factor Inhibitors; D011994:Recombinant Proteins; D012709:Serum Albumin; D005169:Factor VIII